Active ingredient description

Anastrozole is a potent and highly selective non-steroidal aromatase inhibitor. It inhibits the enzyme aromatase, which is responsible for converting androgens to estrogens. Anastrozole is a drug indicated in the treatment of breast cancer in post-menopausal women.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
L Antineoplastic and immunomodulating agents → L02 Endocrine therapy → L02B Hormone antagonists and related agents → L02BG Aromatase inhibitors
Discover more medicines within L02BG03

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Summary of Product Characteristics (SPC)

Structural formula

Graphic representation of the active ingredient's molecular structure

Chemical formula: C₁₇H₁₉N₅
Molecular mass: 293.366 g/mol

3D molecular structure

3D representation of the active ingredient's molecular structure

External identifiers

CAS Substance: 120511-73-1
DrugBank Drug: DB01217
KEGG Drug: D00960
PubChem Compound: 2187
RxNorm Ingredient: 84857
SNOMED-CT Concept: 386910003
Anastrozole (substance)
UNII Identifier: 2Z07MYW1AZ


Anastrozole is an active ingredient of these brands:

United States (US)

Australia (AU)

Austria (AT)

Canada (CA)

Ecuador (EC)

Estonia (EE)

Finland (FI)

France (FR)

Ireland (IE)

Japan (JP)

Lithuania (LT)

Malta (MT)

Mexico (MX)

Netherlands (NL)

Spain (ES)

United Kingdom (UK)

While we strive to include the brand names of medicines across all countries, our index remains incomplete. Therefore, it is possible that this medicine may also be marketed under different names in other countries.